Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?

× No keyword cloud information.

30 in total

1. EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil.

Authors: Sofia Palacio; Luciola Pontes; Edna Prado; Junaid Arshad; Robert Ali; Tony Piha; Carlos Eduardo Bacchi; Raja Mudad; Gilberto Lopes
Journal: Oncologist Date: 2018-11-16

Review 2. Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.

Authors: Liangqing Ge; Ruizheng Shi
Journal: Int J Clin Exp Med Date: 2015-07-15

Review 3. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

Authors: Jeryl Villadolid; Jennifer L Ersek; Mei Ka Fong; Lindsey Sirianno; Ellen S Story
Journal: Transl Lung Cancer Res Date: 2015-10

Review 4. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.

Authors: S Morin-Ben Abdallah; V Hirsh
Journal: Curr Oncol Date: 2018-06-13 Impact factor: 3.677

5. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Authors: Mauricio Burotto; Elisabet E Manasanch; Julia Wilkerson; Tito Fojo
Journal: Oncologist Date: 2015-03-20

6. Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer.

Authors: Yanning Wang; Xiaoling Gong; Yuxuan Hu; Qing Yi; Qianning Zhang; Liyun Miao; Yujie Zhou
Journal: Front Oncol Date: 2022-06-20 Impact factor: 5.738

Review 7. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.

Authors: Gillian M Keating
Journal: Drugs Date: 2014-02 Impact factor: 9.546

8. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.

Authors: John F Deeken; Jan H Beumer; Nicole M Anders; Teresia Wanjiku; Milan Rusnak; Michelle A Rudek
Journal: Cancer Chemother Pharmacol Date: 2015-09-02 Impact factor: 3.333

9. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression.

Authors: Mark A Socinski; Liza C Villaruz; Jeffrey Ross
Journal: Oncologist Date: 2016-11-07

10. SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness.

Authors: Leiming Xia; Fan Yang; Xiao Wu; Suzhi Li; Chen Kan; Hong Zheng; Siying Wang
Journal: Cancer Cell Int Date: 2021-07-03 Impact factor: 5.722